This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Oncology  • Head & Neck Cancer  • Neoplasms of Head & Neck  • Patient Safety/ Medical Error  • Prognosis/ Outcomes  • Drug Therapy  • Adverse Effects  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Craig Derkay, MD

Arch Otolaryngol Head Neck Surg. 2009;135(2):198-201.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Hypothesis: Intralesional cidofovir should be routinely considered in the treatment of recurrent respiratory papillomatosis (RRP).

BACKGROUND

Although surgical management remains the mainstay of therapy for RRP, ultimately as many as 20% of patients with the disease will require some form of adjuvant therapy.¹ The most widely adopted current criteria for initiating adjuvant therapy are a surgery requirement of more than 4 procedures per year, distal multisite spread of disease, and/or rapid regrowth of papilloma disease with airway compromise.² At the present time, there are no medications approved by the US Food and Drug Administration (FDA) with an indication for treatment of RRP.

Figure appears in full text version. Craig Derkay, MD

Cidofovir (Vistide, Gilead, Foster City, California) is a nucleotide analogue that is readily incorporated into the growing DNA chain of mammals and has antiviral activity against the herpesvirus family. Cidofovir has been shown to have irreversible antiproliferative activity against cells infected with the . . . [Full Text of this Article]

PRO

CON

BOTTOM LINE

AUTHOR INFORMATION

Author Affiliation: Departments of Otolaryngology and Pediatrics, Eastern Virginia Medical School, Norfolk.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?